Cellics Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11588 Sorrento Valley Rd Ste 20, San Die...Phone Number
(858) 412-4156Website
www.cellics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Cellics Therapeutics
Cellics Therapeutics is developing a novel therapeutics platform aimed at addressing significant unmet needs in the fields of inflammation and immunology. The company focuses on complex biological challenges to create innovative solutions. Their intended clients include healthcare providers and patients seeking advanced treatments for inflammatory and immunological conditions. Cellics Therapeutics is based in San Diego, California.Explore more
Cellics Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cellics Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Cellics Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Cellics Therapeutics launches new products
Funding: Get notified immidiatlly once Cellics Therapeutics has new funding data
Check if Cellics Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Cellics Therapeutics recently announced quarterly report
Check out if Cellics Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Cellics Therapeutics
Cellics Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Cellics Therapeutics
Find 3 more new buyers
Compare Similar Companies to Cellics Therapeutics
Compare insights from companies similar to Cellics Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cellics Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cellics Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cellics Therapeutics.
Cellics Therapeutics financials insights
Gather financial insights about Cellics Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
Cellics Therapeutics Tech Stack
A closer look at the technologies used by Cellics Therapeutics
Most Recent Scoops
Facilities Relocation / Expansion
Cellics Therapeutics is planning to move offices in January 2025. The move will impact approximately 11 employees at the existing office located at 11588 Sorrento Valley Rd, Suite #20, San Diego, CA.
Facilities Relocation/Expansion
New Hire
Executive Move
New Hire
Executive Move
Open Position
Open Position
Cellics Therapeutics News & Media
Cellics Therapeutics Receives First IND Allowance by FDA for Its Innovative Cellular Nanoparticle (CNP) Technology
SAN DIEGO--(BUSINESS WIRE)--Cellics Therapeutics, Inc., a biotech startup company using the innovative Cellular Nanoparticle (CNP) Technology for the treatment and prevention of infectious and inflammatory diseases, announced today that the U.S. Food and Drug Administration (FDA) has allowed the Investigational New Drug (IND) application for its lead drug product CTI-005, Human Red Blood Cell Nanosponges, for patients hospitalized with methicillin-resistant Staphylococcus aureus (MRSA) or methiCellics Therapeutics Announces the Publication of Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity in Nano Letters
SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Cellics Therapeutics, Inc. (Cellics) announced today that results of the study that evaluates the potential benefits of macrophage and pulmonary epithelial nanosponges in neutralizing SARS-CoV-2 infectivity have been published in Nano Letters, entitled Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity, based on research conducted by its founder, Liangfang Zhang, Ph.D. http://pubs.acs.org/doi/abs/10.1021/acs.nanolett.0c02278
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cellics Therapeutics
Sign Up For FreeTo access detailed company insights
Cellics Therapeutics is developing a novel therapeutics platform aimed at addressing significant unmet needs in the fields of inflammation and immunology. The company focuses on complex biological challenges to create innovative solutions. Their intended clients include healthcare providers and patients seeking advanced treatments for inflammatory... Read More
